Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

STRO-002 is a FolRα-targeting antibody-drug conjugate (ADC), currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe.

Related Keywords

Germany ,Taiwan ,Shanghai ,China ,Hong Kong ,United Kingdom ,Canada ,Macau ,Chinese ,Sutro Biopharma ,Anniej Chang ,Sutro Xpress ,Kaijing Yan ,Tasly Biopharmaceuticals Co Ltd ,Bionova Pharmaceuticals ,Celgene Corporation ,Exchange Commission ,Tasly Pharmaceutical Group Co Ltd ,Merck Kga ,Sutro Biopharma Inc ,Merck Kgaa ,Serono ,Bristol Myers Squibb ,Greater China ,Chief Executive Officer ,Tasly Biopharmaceuticals ,Pro United Kingdom ,South San Francisco ,Orphan Drug Designation ,Fast Track ,Myers Squibb ,Antibody Drug Conjugate ,Private Securities Litigation Reform Act ,Alliance ,Biotechnology ,Cancer ,Drug Discovery ,Manufacturing ,Ovarian Cancer ,Partnership ,Biopharmaceutical ,Celgene ,Merck Serono ,California ,Tasly ,